Madrigal Pharmaceuticals (MDGL) saw its shares drop about 8% in premarket trading after releasing a mixed Q4 2025 report. The company reported a revenue of $321.1 million, surpassing expectations by $8.3 million and marking a 210% year-over-year increase. However, the loss per share of $2.57 fell short of forecasts by $2.03. Despite the challenges, the liver disease therapy Rezdiffra contributed $958.4 million in its first full year. The company ended 2025 with over 36,250 patients and a net loss that decreased by more than 38% to $288.2 million.
https://www.gurufocus.com/news/8632402/madrigal-pharmaceuticals-mdgl-faces-mixed-q4-2025-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.